NEW YORK (GenomeWeb News) – Foundation Medicine and Agios Pharmaceuticals today announced a deal to develop diagnostics for the biopharmaceutical firm's drug candidates.

Under the terms of the deal, the partners seek to identify genomic alterations, which can be used to pick out those patients most likely to respond to Agios' new cancer metabolism inhibitors targeting tumors carrying mutations in either the IDH1 or IDH2 metabolic enzymes. Using this information, Foundation and Agios will then develop and potentially commercialize diagnostics for the drug candidates.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.